SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) Oct. 8, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced today

Oct. 7, 2026 -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRNA therapeutic targeting INHBE (inhibin subunit beta E), with overweight and obesity as its intended future therapeutic indications. Obesity has become one of the world's most significant public health challenges, affecting more than one billion peopl

Two abstracts on long-term follow-up data of AHB-137 treatment for chronic hepatitis B have been selected for late-breaking oral presentations at The Liver Meeting® 2026. Oct. 7, 2026 -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together,"AusperBio"), a near-commercial biopharmaceutical company, today announced that two abstracts reporting long-term follow-up data of AHB-137 treatment have been selected for late-breaking oral presentations at The Liver Meeting® 2026, the annu

Matchpoint Therapeutics announced Wednesday the closing of a series B financing round that has added $150 million to the biotech's coffers in support of efforts to develop oral, small-molecule drugs for autoimmune and inflammatory diseases. The financing was co-led by Nextech Invest and Norwest, with new participants including Invus, BB Biotech, T1D Fund and BOLD Longevity Growth. In addition, existing investors Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures also to

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 in

Shionogi & Co, headquartered in Osaka, Japan, has agreed to acquire IntraBio, a biopharmaceutical company developing and commercialising therapies for neurodegenerative diseases. IntraBio would become a wholly owned subsidiary of Shionogi Inc, a New Jersey, US-based subsidiary of Shionogi. The deal would add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio. Aqneursa was approved by the FDA in September 2024 for neurological manifest

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment

TCGX today announced the closing of the TCGX Asia Life Sciences Fund I, an oversubscribed $600 million investment vehicle backed by a diverse group of international institutional investors. The fund will focus on investing in innovative biotechnology companies based in Asia. In connection with the launch of TCGX Asia Life Sciences Fund I, L.P., TCGX is expanding its operations to Asia with new offices in Hong Kong and Shanghai to take advantage of the explosive growth of early-stage drug discov

NIH-funded randomized, double-blind, placebo-controlled Phase 1 single-ascending-dose study expected to begin dosing healthy volunteers in November 2026 Preliminary topline data from initial cohorts anticipated in early 2027 Oct. 7, 2026 -- Dignify Therapeutics ("Dignify", the "Company"), a biopharmaceutical development company focused on restoring bowel and bladder control for people with neurological conditions, today announced that its Investigational New Drug (IND) application for DTI-117 h

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, and the 15-20 National Hospital (l’Hôpital national des 15-20) in Paris today announced the publication of the results of the GS030 PIONEER trial in the prestigious medical journal The New England Journal of Medicine (NEJM). Available in the October 8, 2026